Case Report of HBsAg Loss in a Young Chronic Hepatitis B Patient taking Tenofovir AlafenamideJournal: International Journal of Science and Research (IJSR) (Vol.11, No. 1)
Publication Date: 2022-01-05
Authors : Arijit Kumar Das; Ashutosh Kumar Singh;
Page : 510-512
Keywords : Chronic hepatitis B; seroconversion; Tenofovir Alafenamide;
Introduction: In patients with chronic hepatitis B, loss of hepatitis B surface antigen (HBsAg) is considered a functional cure. HBsAg loss is uncommon with existing therapies, and predictive factors associated with HBsAg seroconversion are unknown. Case Report: MR.XX, 26 years old man presented withhyperpigmented macules and pruritis on 23rd August, 2017. The Laboratory findings were suggestive of hepatitis B, he was started on Tenofovir Alafenamide 25 mg on 28th March, 2018 after confirming the chronicity and was subsequently followed up. After 3 years of treatment HBV DNA was not detected on 13th March, 2021 and HBsAg was negative as tested on 25th March, 2021. Discussion: Hepatic insult by HBV resulting in chronic hepatitis B does correlate with the abnormal Sr globulin levels and reversal can be detected on proper compliance with antivirals. Conclusion: Timely detection and treatment with appropriately selected antiviral can lead to HBsAg loss and give better survival benefit to the patient.
Other Latest Articles
Last modified: 2022-02-15 19:04:11